HomeCompareAKSJF vs PFE

AKSJF vs PFE: Dividend Comparison 2026

AKSJF yields 1345.42% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKSJF wins by $261992149.85M in total portfolio value
10 years
AKSJF
AKSJF
● Live price
1345.42%
Share price
$2.95
Annual div
$39.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$261992149.90M
Annual income
$228,572,448,613,362.30
Full AKSJF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AKSJF vs PFE

📍 AKSJF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKSJFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKSJF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKSJF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKSJF
Annual income on $10K today (after 15% tax)
$114,361.02/yr
After 10yr DRIP, annual income (after tax)
$194,286,581,321,357.97/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AKSJF beats the other by $194,286,581,299,038.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKSJF + PFE for your $10,000?

AKSJF: 50%PFE: 50%
100% PFE50/50100% AKSJF
Portfolio after 10yr
$130996074.97M
Annual income
$114,286,224,319,810.52/yr
Blended yield
87.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AKSJF
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKSJF buys
0
PFE buys
0
No recent congressional trades found for AKSJF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKSJFPFE
Forward yield1345.42%6.13%
Annual dividend / share$39.69$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$261992149.90M$49.6K
Annual income after 10y$228,572,448,613,362.30$26,258.71
Total dividends collected$259531317.43M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AKSJF vs PFE ($10,000, DRIP)

YearAKSJF PortfolioAKSJF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$145,242$134,542.38$9,153$693.39+$136.1KAKSJF
2$1,981,695$1,826,285.46$8,593$849.25+$1.97MAKSJF
3$25,408,205$23,287,791.77$8,336$1,066.78+$25.40MAKSJF
4$306,236,601$279,049,821.60$8,437$1,384.80+$306.23MAKSJF
5$3,470,938,760$3,143,265,596.63$9,013$1,875.40+$3470.93MAKSJF
6$37,009,528,330$33,295,623,856.57$10,306$2,680.72+$37009.52MAKSJF
7$371,395,302,942$331,795,107,629.62$12,820$4,101.38+$371395.29MAKSJF
8$3,509,174,205,017$3,111,781,230,868.68$17,673$6,826.70+$3509174.19MAKSJF
9$31,233,365,687,823$27,478,549,288,455.11$27,543$12,591.86+$31233365.66MAKSJF
10$261,992,149,899,333$228,572,448,613,362.30$49,560$26,258.71+$261992149.85MAKSJF

AKSJF vs PFE: Complete Analysis 2026

AKSJFStock

Sberbank of Russia, together with its subsidiaries, provides corporate and retail banking products and services to individuals, small businesses, corporate clients, and financial institutions. The company offers deposit products; pension accounts; payment, transfer, brokerage, and asset management services; car, housing, education, and consumer loans; mortgages; debit and credit cards, and overdraft service; and refinancing products. It also provides derivative, financial instrument, foreign currency, precious metal, corporate structured, and commodities and securities products, as well as debt and capital markets funding, documentary, and other commission services. In addition, it offers life, property, bank card, accident, liability, trust management, investment and universal life, travel, and mutual investment funds insurance products, as well as individual pension plans and corporate pension programs. Additionally, the company provides business bank accounts, platform for exporters and importers, merchant acquiring and international trading services, and corporate cards for small businesses; and loans, investment products and capital markets services, fund investment services, and banking services for corporate clients. It also provides trade finance, interbank lending, currency risk hedging, and treasury services; deposits, custody services, and electronic trading systems; and settlement and cash collection services to financial institutions. As of December 31, 2020, the company operated 11 Regional banks and 14,162 branches in Russia. The company also has operations in 18 countries internationally. Sberbank of Russia was founded in 1841 and is headquartered in Moscow, Russia.

Full AKSJF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AKSJF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKSJF vs SCHDAKSJF vs JEPIAKSJF vs OAKSJF vs KOAKSJF vs MAINAKSJF vs JNJAKSJF vs MRKAKSJF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.